The popularity of Sildenafil initially sparked a surge for major pharmaceutical companies, but recent developments present a complicated picture for investors. Lower-cost competitors are eating into earnings, and https://teganwlpr258914.digiblogbox.com/65575048/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet